Sirt1 inhibitor, Sirtinol, induces senescence-like growth arrest with attenuated Ras-MAPK signaling in human cancer cells

Oncogene

Volumn 25, Issue 2, 2006, Pages 176-185

  Ota, H ^a,b   Tokunaga, E ^a,c   Chang, K ^a   Hikasa, M ^a   Iijima, K ^b   Eto, M ^b   Kozaki, K ^b   Akishita, M ^b   Ouchi, Y ^b   Kaneki, M ^a,c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF TOKYO   (Japan)

^c SHRINERS HOSPITALS FOR CHILDREN   (United States)

Author keywords

Akt PKB; Cellular senescence; MAPK; Ras; Sirt1; Sirtinol

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN INHIBITOR; PROTEIN KINASE B; RAS PROTEIN; SIRTINOL; SIRTUIN; SIRTUIN 1 INHIBITOR; SOMATOMEDIN C; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER INHIBITION; CELL STRAIN MCF 7; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INDUCTION; HUMAN; HUMAN CELL; LUNG CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SENESCENCE; SIGNAL TRANSDUCTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; BENZAMIDES; BETA-GALACTOSIDASE; BREAST NEOPLASMS; CELL AGING; ENZYME ACTIVATION; EPIDERMAL GROWTH FACTOR; GENES, RAS; HISTONE DEACETYLASES; HUMANS; INSULIN-LIKE GROWTH FACTOR I; LUNG NEOPLASMS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NAPHTHOLS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION; SIRTUINS; TUMOR CELLS, CULTURED; TYROSINE;

MINK CELL FOCUS-FORMING VIRUS;

EID: 30544445468     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1209049     Document Type: Article

References (67)

1. Alexander K, Hinds PW. (2001). Mol Cell Biol 21: 3616-3631.
2. Aviv H, Khan MY, Skurnick J, Okuda K, Kimura M, Gardner J et al. (2001). Atherosclerosis 159: 281-287.
3. Beausejour CM, Krtolica A, Galimi F, Narita M, Lowe SW, Yaswen P et al. (2003). EMBO J 22: 4212-4222.
4. Bedalov A, Gatbonton T, Irvine WP, Gottschling DE, Simon JA. (2001). Proc Natl Acad Sci USA 98: 15113-15118.
5. Ben-Porath I, Weinberg RA. (2004). J Clin Invest 113: 8-13.
6. Blander G, Guarente L. (2004). Annu Rev Biochem 73: 417-435.
7. Brunet A, Sweeney LB, Sturgill JF, Chua KF, Greer PL, Lin Y et al. (2004). Science 303: 2011-2015.
8. Carrano AC, Eytan E, Hershko A, Pagano M. (1999). Nat Cell Biol 1: 193-199.
9. Chang BD, Broude EV, Dokmanovic M, Zhu H, Ruth A, Xuan Y et al. (1999a). Cancer Res 59: 3761-3767.
10. Chang BD, Xuan Y, Broude EV, Zhu H, Schott B, Fang J et al. (1999b). Oncogens 18: 4808-4818.
11. Cheng HL, Mostoslavsky R, Saito S, Manis JP, Gu Y, Patel P et al. (2003). Proc Natl Acad Sci USA 100: 10794-10799.
12. Christov KT, Shilkaitis AL, Kim ES, Steele VE, Lubet RA. (2003). Eur J Cancer 39: 230-239.
13. Cohen HY, Lavu S, Bitterman KJ, Hekking B, Imahiyerobo TA, Miller C et al. (2004). Mol Cell 13: 627-638.
14. Collado M, Medema RH, Garcia-Cao I, Dubuisson ML, Barradas M, Glassford J et al. (2000). J Biol Chem 275: 21960-21968.
15. Daitoku H, Hatta M, Matsuzaki H, Aratani S, Ohshima T, Miyagishi M et al. (2004). Proc Natl Acad Sci USA 101: 10042-10047.
16. Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C et al. (1995). Proc Natl Acad Sci USA 92: 9363-9367.
17. Elegbede JA, Hayes K, Schell K, Oberley TD, Verma AK. (2002). Life Sci 71: 421-436.
18. Elmore LW, Rehder CW, Di X, McChesney PA, Jackson-Cook CK, Gewirtz DA et al. (2002). J Biol Chem 277: 35509-35515.
19. Fujita N, Sato S, Katayama K, Tsuruo T. (2002). J Biol Chem 277: 28706-28713.
20. Gnudi L, Frevert EU, Houseknecht KL, Erhardt P, Kahn BB. (1997). Mol Endocrinol 11: 67-76.
21. Goldstein S, Moerman EJ, Fujii S, Sobel BE. (1994). J Cell Physiol 161: 571-579.
22. Grozinger CM, Chao ED, Blackwell HE, Moazed D, Schreiber SL. (2001). J Biol Chem 276: 38837-38843.
23. Han Z, Wei W, Dunaway S, Darnowski JW, Calabresi P, Sedivy J et al. (2002). J Biol Chem 277: 17154-17160.
24. Imai S, Armstrong CM, Kaeberlein M, Guarente L. (2000). Nature 403: 795-800.
25. Jirawatnotai S, Moons DS, Stocco CO, Franks R, Hales DB, Gibori G et al. (2003). J Biol Chem 278: 17021-17027.
26. Kahlem P, Dorken B, Schmitt CA. (2004). J Clin Invest 113: 169-174.
27. Kelly WK, Richon VM, O'Connor O, Curley T, MacGregor-Curtelli B, Tong W et al. (2003). Clin Cancer Res 9: 3578-3588.
28. Kim JH, Lee GE, Kim SW, Chung IK. (2003). Biochem J 373: 523-529.
29. Klesse LJ, Meyers KA, Marshall CJ, Parada LF. (1999). Oncogene 18: 2055-2068.
30. Landry J, Sutton A, Tafrov ST, Heller RC, Stebbins J, Pillus L et al. (2000). Proc Natl Acad Sci USA 97: 5807-5811.
31. Lange-Carter CA, Johnson GL. (1994). Science 265: 1458-1461.
32. Langley E, Pearson M, Faretta M, Bauer UM, Frye RA, Minucci S et al. (2002). EMBO J 21: 2383-2396.
33. Luo J, Nikolaev AY, Imai S, Chen D, Su F, Shiloh A et al. (2001). Cell 107: 137-148.
34. Mallette FA, Goumard S, Gaumont-Leclerc MF, Moiseeva O, Ferbeyre G. (2004). Oncogene 23: 91-99.
35. Mathon NF, Lloyd AC. (2001). Nat Rev Cancer 1: 203-213.
36. McLaughlin F, La Thangue NB. (2004). Curr Drug Targets Inflamm Allergy 3: 213-219.
37. Motta MC, Divecha N, Lemieux M, Kamel C, Chen D, Gu W et al. (2004). Cell 116: 551-563.
38. Munro J, Barr NI, Ireland H, Morrison V, Parkinson EK. (2004). Exp Cell Res 295: 525-538.
39. Pelicci PG. (2004). J Clin Invest 113: 4-7.
40. Picard F, Kurtev M, Chung N, Topark-Ngarm A, Senawong T, Machado De Oliveira R et al. (2004). Nature 429: 771-776.
41. Piekarz R, Bates S. (2004). Curr Pharm Des 10: 2289-2298.
42. Piekarz RL, Robey R, Sandor V, Bakke S, Wilson WH, Dahmoush L et al. (2001). Blood 98: 2865-2868.
43. Roninson IB. (2002). Drug Resist Updat 5: 204-208.
44. Roninson IB. (2003). Cancer Res 63: 2705-2715.
45. Rosato RR, Grant S. (2004). Expert Opin Investig Drugs 13: 21-38.
46. Sakaue H, Hara K, Noguchi T, Matozaki T, Kotani K, Ogawa W et al. (1995). J Biol Chem 270: 11304-11309.
47. Sandor V, Bakke S, Robey RW, Kang MH, Blagosklonny MV, Bender J et al. (2002). Clin Cancer Res 8: 718-728.
48. Schmitt CA, Fridman JS, Yang M, Lee S, Baranov E, Hoffman RM et al. (2002). Cell 109: 335-346.
49. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. (1997). Cell 88: 593-602.
50. Seshadri T, Campisi J. (1990). Science 247: 205-209.
51. Sharpless NE, DePinho RA. (2004). J Clin Invest 113: 160-168.
52. Shay JW, Roninson IB. (2004). Oncogene 23: 2919-2933.
53. Sugita H, Fujimoto M, Yasukawa T, Shimizu N, Sugita M, Yasuhara S et al. (2005). J Biol Chem 280: 14203-14211.
54. Takahashi T, Nowakowski RS, Caviness Jr VS. (1992). J Neurocytol 21: 185-197.
55. te Poele RH, Okorokov AL, Jardine L, Cummings J, Joel SP. (2002). Cancer Res 62: 1876-1883.
56. Torres C, Francis MK, Lorenzini A, Tresini M, Cristofalo VJ. (2003). Exp Cell Res 290: 195-206.
57. Tresini M, Lorenzini A, Frisoni L, Allen RG, Cristofalo VJ. (2001). Exp Cell Res 269: 287-300.
58. van der Horst A, Tertoolen LG, de Vries-Smits LM, Frye RA, Medema RH, Burgering BM. (2004). J Biol Chem 279: 28873-28879.
59. Vanhaecke T, Papeleu P, Elaut G, Rogiers V. (2004). Curr Med Chem 11: 1629-1643.
60. Vaziri H, Dessain SK, Ng Eaton E, Imai SI, Frye RA, Pandita TK et al. (2001). Cell 107: 149-159.
61. Vigushin DM, Coombes RC. (2004). Curr Cancer Drug Targets 4: 205-218.
62. Wagner M, Hampel B, Bernhard D, Hala M, Zwerschke W, Jansen-Durr P. (2001). Exp Gerontol 36: 1327-1347.
63. Wainwright LJ, Lasorella A, Iavarone A. (2001). Proc Natl Acad Sci USA 98: 9396-9400.
64. Wang X, Tsao SW, Wong YC, Cheung AL. (2003). Curr Cancer Drug Targets 3: 153-159.
65. Wright WE, Shay JW. (2001). Curr Opin Genet Dev 11: 98-103.
66. Yasukawa T, Tokunaga E, Ota H, Sugita H, Martyn JA, Kaneki M. (2005). J Biol Chem 280: 7511-7518.
67. Zhu WY, Jones CS, Kiss A, Matsukuma K, Amin S, De Luca LM. (1997). Exp Cell Res 234: 293-299.